Newsroom
  • Press Releases
  • Presentations
Investors
  • Overview
  • Annual Meeting of Stockholders
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
Contact

CytoDyn Inc.

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
  • Our Team
    • Leadership Team
    • Board of Directors
  • Publications
  • Scientific Advisory Board
  • Newsroom
  • Investors
  • Contact
Latest News

Press Releases

Newsroom

Newsroom

  • Press Releases
  • Presentations

CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species”

Apr 12, 2022 8:30am EDT

CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program

Mar 30, 2022 5:00pm EDT

CytoDyn to Hold Webcast to Provide Company Update

Mar 30, 2022 8:30am EDT

CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab

Jan 25, 2022 6:06pm EST
RSS
  • Prev
    • 1
    • 2
    © 2023 CytoDyn Inc. All Rights Reserved.
    • Twitter
    • Facebookj
    Privacy Policy Disclaimer Sitemap